Literature DB >> 32086377

Norrin restores blood-retinal barrier properties after vascular endothelial growth factor-induced permeability.

Mónica Díaz-Coránguez1, Cheng-Mao Lin1, Stefan Liebner2, David A Antonetti3.   

Abstract

Vascular endothelial growth factor (VEGF) contributes to blood-retinal barrier (BRB) dysfunction in several blinding eye diseases, including diabetic retinopathy. Signaling via the secreted protein norrin through the frizzled class receptor 4 (FZD4)/LDL receptor-related protein 5-6 (LRP5-6)/tetraspanin 12 (TSPAN12) receptor complex is required for developmental vascularization and BRB formation. Here, we tested the hypothesis that norrin restores BRB properties after VEGF-induced vascular permeability in diabetic rats or in animals intravitreally injected with cytokines. Intravitreal co-injection of norrin with VEGF completely ablated VEGF-induced BRB permeability to Evans Blue-albumin. Likewise, 5-month diabetic rats exhibited increased permeability of FITC-albumin, and a single norrin injection restored BRB properties. These results were corroborated in vitro, where co-stimulation of norrin with VEGF or stimulation of norrin after VEGF exposure restored barrier properties, indicated by electrical resistance or 70-kDa RITC-dextran permeability in primary endothelial cell culture. Interestingly, VEGF promoted norrin signaling by increasing the FZD4 co-receptor TSPAN12 at cell membranes in an MAPK/ERK kinase (MEK)/ERK-dependent manner. Norrin signaling through β-catenin was required for BRB restoration, but glycogen synthase kinase 3 α/β (GSK-3α/β) inhibition did not restore BRB properties. Moreover, levels of the tight junction protein claudin-5 were increased with norrin and VEGF or with VEGF alone, but both norrin and VEGF were required for enriched claudin-5 localization at the tight junction. These results suggest that VEGF simultaneously induces vascular permeability and promotes responsiveness to norrin. Norrin, in turn, restores tight junction complex organization and BRB properties in a β-catenin-dependent manner.
© 2020 Díaz-Coránguez et al.

Entities:  

Keywords:  Wnt signaling; blood-retinal barrier; cell signaling; diabetic retinopathy; endothelium; norrin; permeability; retina; tetraspanin; tetraspanin 12 (TSPAN12); tight junction; vascular endothelial growth factor (VEGF)

Mesh:

Substances:

Year:  2020        PMID: 32086377      PMCID: PMC7135996          DOI: 10.1074/jbc.RA119.011273

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

1.  Isolation and characterization of retinal endothelial cells.

Authors:  David A Antonetti; Ellen B Wolpert
Journal:  Methods Mol Med       Date:  2003

2.  Reck enables cerebrovascular development by promoting canonical Wnt signaling.

Authors:  Florian Ulrich; Jorge Carretero-Ortega; Javier Menéndez; Carlos Narvaez; Belinda Sun; Eva Lancaster; Valerie Pershad; Sean Trzaska; Evelyn Véliz; Makoto Kamei; Andrew Prendergast; Kameha R Kidd; Kenna M Shaw; Daniel A Castranova; Van N Pham; Brigid D Lo; Benjamin L Martin; David W Raible; Brant M Weinstein; Jesús Torres-Vázquez
Journal:  Development       Date:  2015-12-10       Impact factor: 6.868

3.  Plasmalemma Vesicle-Associated Protein Has a Key Role in Blood-Retinal Barrier Loss.

Authors:  Joanna Wisniewska-Kruk; Anne-Eva van der Wijk; Henk A van Veen; Theo G M F Gorgels; Ilse M C Vogels; Danielle Versteeg; Cornelis J F Van Noorden; Reinier O Schlingemann; Ingeborg Klaassen
Journal:  Am J Pathol       Date:  2016-02-12       Impact factor: 4.307

4.  Interplay of the Norrin and Wnt7a/Wnt7b signaling systems in blood-brain barrier and blood-retina barrier development and maintenance.

Authors:  Yanshu Wang; Chris Cho; John Williams; Philip M Smallwood; Chi Zhang; Harald J Junge; Jeremy Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-26       Impact factor: 11.205

5.  Molecular modelling of the Norrie disease protein predicts a cystine knot growth factor tertiary structure.

Authors:  T Meitinger; A Meindl; P Bork; B Rost; C Sander; M Haasemann; J Murken
Journal:  Nat Genet       Date:  1993-12       Impact factor: 38.330

6.  TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling.

Authors:  Harald J Junge; Stacey Yang; Jeremy B Burton; Kim Paes; Xiao Shu; Dorothy M French; Mike Costa; Dennis S Rice; Weilan Ye
Journal:  Cell       Date:  2009-10-16       Impact factor: 41.582

7.  Retinal vasculature changes in Norrie disease mice.

Authors:  M Richter; J Gottanka; C A May; U Welge-Lüssen; W Berger; E Lütjen-Drecoll
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-11       Impact factor: 4.799

8.  Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5.

Authors:  Andrea Taddei; Costanza Giampietro; Annarita Conti; Fabrizio Orsenigo; Ferruccio Breviario; Valentina Pirazzoli; Michael Potente; Christopher Daly; Stefanie Dimmeler; Elisabetta Dejana
Journal:  Nat Cell Biol       Date:  2008-07-06       Impact factor: 28.824

9.  Whole Exome Sequencing Analysis Identifies Mutations in LRP5 in Indian Families with Familial Exudative Vitreoretinopathy.

Authors:  Lin Zhang; Yeming Yang; Shujin Li; Zhengfu Tai; Lulin Huang; Yuqing Liu; Xiong Zhu; Yanan Di; Chao Qu; Zhilin Jiang; Yuanfeng Li; Guolin Zhang; Ramasamy Kim; Periasamy Sundaresan; Zhenglin Yang; Xianjun Zhu
Journal:  Genet Test Mol Biomarkers       Date:  2016-05-26

10.  Wnt/beta-catenin signaling controls development of the blood-brain barrier.

Authors:  Stefan Liebner; Monica Corada; Thorsten Bangsow; Jane Babbage; Andrea Taddei; Cathrin J Czupalla; Marco Reis; Angelina Felici; Hartwig Wolburg; Marcus Fruttiger; Makoto M Taketo; Harald von Melchner; Karl Heinz Plate; Holger Gerhardt; Elisabetta Dejana
Journal:  J Cell Biol       Date:  2008-10-27       Impact factor: 10.539

View more
  10 in total

1.  Structure and function of the retina of low-density lipoprotein receptor-related protein 5 (Lrp5)-deficient rats.

Authors:  John L Ubels; Cheng-Mao Lin; David A Antonetti; Monica Diaz-Coranguez; Cassandra R Diegel; Bart O Williams
Journal:  Exp Eye Res       Date:  2022-02-06       Impact factor: 3.770

2.  Impairment of the Retinal Endothelial Cell Barrier Induced by Long-Term Treatment with VEGF-A165 No Longer Depends on the Growth Factor's Presence.

Authors:  Heidrun L Deissler; Matus Rehak; Armin Wolf
Journal:  Biomolecules       Date:  2022-05-23

Review 3.  Spectrum of Mutations in NDP Resulting in Ocular Disease; a Systematic Review.

Authors:  James Wawrzynski; Aara Patel; Abdul Badran; Isaac Dowell; Robert Henderson; Jane C Sowden
Journal:  Front Genet       Date:  2022-05-16       Impact factor: 4.772

4.  The neuroscience of diabetic retinopathy.

Authors:  David A Antonetti
Journal:  Vis Neurosci       Date:  2021-01-18       Impact factor: 3.241

5.  Anti-VEGF treatment suppresses remodeling factors and restores epithelial barrier function through the E-cadherin/β-catenin signaling axis in experimental asthma models.

Authors:  Ahmet Türkeli; Özge Yilmaz; Meral Karaman; Esra Toprak Kanik; Fatih Firinci; Sevinç İnan; Hasan Yüksel
Journal:  Exp Ther Med       Date:  2021-04-29       Impact factor: 2.447

6.  NMMHC IIA triggered lipid metabolize reprogramming resulting in vascular endothelial cellular tight junction injury.

Authors:  Yanni Lv; Daojun Hong; Longsheng Fu; Yisong Qian
Journal:  Mol Biol Rep       Date:  2022-01-22       Impact factor: 2.316

Review 7.  Current understanding of the molecular and cellular pathology of diabetic retinopathy.

Authors:  David A Antonetti; Paolo S Silva; Alan W Stitt
Journal:  Nat Rev Endocrinol       Date:  2021-01-19       Impact factor: 47.564

Review 8.  Pericyte-Endothelial Interactions in the Retinal Microvasculature.

Authors:  Hu Huang
Journal:  Int J Mol Sci       Date:  2020-10-08       Impact factor: 5.923

Review 9.  Wnt Signaling in Inner Blood-Retinal Barrier Maintenance.

Authors:  Felix Yemanyi; Kiran Bora; Alexandra K Blomfield; Zhongxiao Wang; Jing Chen
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 6.208

10.  SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy.

Authors:  Huy Nguyen; Hui Chen; Meghah Vuppalapaty; Elizabeth Whisler; Kelsey Ronarda Logas; Parthasarathy Sampathkumar; Russell Byron Fletcher; Asmiti Sura; Nicholas Suen; Suhani Gupta; Tom Lopez; Jay Ye; Shengjiang Tu; Menaka Bolaki; Wen-Chen Yeh; Yang Li; Sung-Jin Lee
Journal:  Transl Vis Sci Technol       Date:  2022-09-01       Impact factor: 3.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.